Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAL-T + Serplulimab in advanced solid tumors
NCT06716619Phase 1Recruiting
- Sponsor
- Guangzhou FineImmune Biotechnology
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FIT003 in solid tumor, melanoma, head and neck cancer (HNC) and 2 more, sponsored by Guangzhou FineImmune Biotechnology. Primary endpoints: Adverse Events at 54 weeks and Serious Adverse Events at 54 weeks. Started Feb 2025; status: recruiting.
02
Drugs
FIT003
03
Conditions
solid tumormelanomahead and neck cancer (HNC)Cervical Cancer (CC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06716619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716619.